Advertisement
Canada markets close in 1 minute
  • S&P/TSX

    21,811.34
    +102.90 (+0.47%)
     
  • S&P 500

    4,968.46
    -42.66 (-0.85%)
     
  • DOW

    38,000.53
    +225.15 (+0.60%)
     
  • CAD/USD

    0.7273
    +0.0010 (+0.13%)
     
  • CRUDE OIL

    83.21
    +0.48 (+0.58%)
     
  • Bitcoin CAD

    88,475.90
    +1,292.73 (+1.48%)
     
  • CMC Crypto 200

    1,379.92
    +67.30 (+5.12%)
     
  • GOLD FUTURES

    2,403.00
    +5.00 (+0.21%)
     
  • RUSSELL 2000

    1,938.51
    -4.45 (-0.23%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,288.81
    -312.69 (-2.00%)
     
  • VOLATILITY

    19.14
    +1.14 (+6.33%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Medtronic Earnings, Revenue Beat in Q2

Medtronic Earnings, Revenue Beat in Q2
Medtronic Earnings, Revenue Beat in Q2

Investing.com - Medtronic reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.

The firm reported earnings per share of $1.31 on revenue of $7.71B. Analysts polled by Investing.com forecast EPS of $1.28 on revenue of $7.66B. That compared to EPS of $1.22 on revenue of $7.5B in the same period a year earlier. The company had reported EPS of $1.26 on revenue of $7.49B in the previous quarter.

Medtronic follows other major Healthcare sector earnings this month

On October 29, Merck&Co reported third quarter EPS of $1.51 on revenue of $12.4B, compared to forecasts of EPS of $1.24 on revenue of $11.64B.

ADVERTISEMENT

Novartis ADR earnings beat analysts' expectations on October 22, with third quarter EPS of $1.41 on revenue of $12.17B. Investing.com analysts expected EPS of $1.32 on revenue of $11.7B

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Sustainable investors face squeeze as larger firms move in

Return of short-selling bans: market protection or 'war against truth'?

How to make the most of a zero-commission world